Raffaele Califano

机构：Cancer Research UK, University of Manchester, Cancer Research UK Manchester Institute, The Christie NHS Foundation Trust, CRUK Lung Cancer Centre of Excellence · ORCID：0000-0003-2611-5319

发表论文 267 篇 · 总被引 14420 次 · h-index 44

代表论文

• Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC (2024 · New England Journal of Medicine · 被引 453)
• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 136)
• Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial (2024 · The Lancet Respiratory Medicine · 被引 128)
• Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA (2024 · Annals of Oncology · 被引 101)
• Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial (2025 · The Lancet · 被引 100)
• Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study (2024 · Lung Cancer · 被引 81)